In Brief: Ciba Vision's Livostin
Executive Summary
Ciba Vision's Livostin: Promotion of Livostin (levocabastine ophthalmic suspension, .05%) announcing removal of labeling restricting use to two weeks will begin before start of fall allergy season through ads in professional journals, Ciba Vision says. FDA approved SNDA 20-219/S-003 June 10 for Livostin, which is indicated for relief of seasonal allergic conjunctivitis symptoms. Approval also changes incidence of "mild, transient stinging and burning" from 15% to 29% in adverse reactions section of labeling...